Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
Condit RC, Kim D, Robertson JS, Excler JL, Gurwith M, Monath TP, Pavlakis G, Fast PE, Smith J, Smith ER, Chen RT, Kochhar S; Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO) Working Group. Electronic address: bc-coordinator@taskforce.org. Condit RC, et al. Among authors: kochhar s. Vaccine. 2020 Nov 17;38(49):7708-7715. doi: 10.1016/j.vaccine.2020.08.009. Epub 2020 Sep 6. Vaccine. 2020. PMID: 32907759 Free PMC article. Review.
Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.
Kochhar S, Excler JL, Bok K, Gurwith M, McNeil MM, Seligman SJ, Khuri-Bulos N, Klug B, Laderoute M, Robertson JS, Singh V, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Kochhar S, et al. Vaccine. 2019 Sep 10;37(38):5796-5802. doi: 10.1016/j.vaccine.2018.08.085. Epub 2018 Nov 26. Vaccine. 2019. PMID: 30497831 Free PMC article.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
Kim D, Robertson JS, Excler JL, Condit RC, Fast PE, Gurwith M, Pavlakis G, Monath TP, Smith J, Wood D, Smith ER, Chen RT, Kochhar S; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Kim D, et al. Among authors: kochhar s. Vaccine. 2020 Jul 22;38(34):5556-5561. doi: 10.1016/j.vaccine.2020.06.017. Epub 2020 Jun 19. Vaccine. 2020. PMID: 32571717 Free PMC article. Review.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Kochhar S, Kim D, Excler JL, Condit RC, Robertson JS, Drew S, Whelan M, Wood D, Fast PE, Gurwith M, Klug B, Khuri-Bulos N, Smith ER, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Kochhar S, et al. Vaccine. 2020 Jul 31;38(35):5734-5739. doi: 10.1016/j.vaccine.2020.06.044. Epub 2020 Jul 9. Vaccine. 2020. PMID: 32653276 Free PMC article. Review.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Kochhar S, Excler JL, Kim D, Robertson JS, Fast PE, Condit RC, Drew S, Wood D, Gurwith M, Klug B, Whelan M, Khuri-Bulos N, Mallett Moore T, Smith ER, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Electronic address: brightoncollaborationv3swg@gmail.com. Kochhar S, et al. Vaccine. 2020 Sep 3;38(39):6184-6189. doi: 10.1016/j.vaccine.2020.07.028. Epub 2020 Jul 31. Vaccine. 2020. PMID: 32747214 Free PMC article.
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
Gurwith M, Condit RC, Excler JL, Robertson JS, Kim D, Fast PE, Drew S, Wood D, Klug B, Whelan M, Mallett Moore T, Khuri-Bulos N, Smith ER, Chen RT, Kochhar S; Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG. Gurwith M, et al. Among authors: kochhar s. Vaccine. 2020 Nov 17;38(49):7702-7707. doi: 10.1016/j.vaccine.2020.09.042. Epub 2020 Oct 16. Vaccine. 2020. PMID: 33070999 Free PMC article. Review.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
Hernandez LM, Sumathy K, Sahastrabuddhe S, Excler JL, Kochhar S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO, ex-V3SWG). Hernandez LM, et al. Among authors: kochhar s. Vaccine. 2022 Aug 19;40(35):5263-5274. doi: 10.1016/j.vaccine.2022.06.006. Epub 2022 Jun 15. Vaccine. 2022. PMID: 35715351 Free PMC article. Clinical Trial.
Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.
Clarke DK, Hendry RM, Singh V, Rose JK, Seligman SJ, Klug B, Kochhar S, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group. Clarke DK, et al. Among authors: kochhar s. Vaccine. 2016 Dec 12;34(51):6597-6609. doi: 10.1016/j.vaccine.2016.06.071. Epub 2016 Jul 6. Vaccine. 2016. PMID: 27395563 Free PMC article. Review.
Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis.
Klug B, Robertson JS, Condit RC, Seligman SJ, Laderoute MP, Sheets R, Williamson AL, Gurwith M, Kochhar S, Chapman L, Carbery B, Mac LM, Chen RT; Brighton Collaboration Viral Vaccine Vector Safety Working Group. Electronic address: brightoncollaborationv3swg@gmail.com. Klug B, et al. Among authors: kochhar s. Vaccine. 2016 Dec 12;34(51):6617-6625. doi: 10.1016/j.vaccine.2016.02.015. Epub 2016 Jun 15. Vaccine. 2016. PMID: 27317264 Free PMC article. Review.
351 results